Australia markets closed

Biogen Inc. (BIIB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
261.22-4.93 (-1.85%)
At close: 04:00PM EDT
260.81 -0.41 (-0.16%)
Pre-market: 04:15AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close266.15
Bid242.00 x 800
Ask292.40 x 800
Day's range261.01 - 267.25
52-week range187.16 - 311.88
Avg. volume991,006
Market cap37.743B
Beta (5Y monthly)0.19
PE ratio (TTM)12.37
EPS (TTM)21.11
Earnings date01 May 2023 - 05 May 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est321.07
  • GlobeNewswire

    Biogen Provides Update on FDA Advisory Committee Meeting on Tofersen for SOD1-ALS

    SOD1-ALS is a rare genetic form of the disease affecting approximately 330 people in the United StatesCAMBRIDGE, Mass., March 22, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced today the outcome of the U.S. Food and Drug Administration’s (FDA) Peripheral and Central Nervous System Drugs Advisory Committee meeting on tofersen, an investigational product for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS). On the question, “Is the available evidenc

  • Zacks

    Biogen Inc. (BIIB) Stock Sinks As Market Gains: What You Should Know

    Biogen Inc. (BIIB) closed the most recent trading day at $266.15, moving -0.66% from the previous trading session.

  • Motley Fool

    Should You Buy Biogen Before a Big July Decision?

    Over time, Biogen (NASDAQ: BIIB) created a true success story. Competition for Biogen's MS blockbuster Tecfidera, and for other key products, entered the market. Now, though, Biogen may have found that new growth source.